Hosted on MSN1mon
Glox to develop precision antibiotics for cystic fibrosis
Glox Therapeutics is set to receive a share of the £3m ($3.67m) Collaborative Discovery Programme (CDP) funding introduced by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate. The ...
Morningstar1mon
Glox Therapeutics Awarded Share of £3M Collaborative Discovery Programme Funding from Cystic Fibrosis Antimicrobial Resistance Syndicate
Glox Therapeutics will receive up to £500,000 of the fund to accelerate the development of its novel precision antibiotics, helping to address the growing need for effective treatments to ...
Morningstar1mon
Glox Therapeutics Strengthens Team Appointing Dr Michael Murray as Chair and Dr Nel Moore as Scientific Advisory Board Member
Morningstar brands and products Company Portfolio ...
PharmiWeb1mon
Glox Therapeutics Strengthens Team Appointing Dr Michael Murray as Chair and Dr Nel Moore as Scientific Advisory Board Member
Glasgow, UK, 11 February 2025: Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced the appointment of ...